tiprankstipranks
Trending News
More News >
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush
PremiumThe FlyOvid Therapeutics price target lowered to $3 from $4 at Wedbush
2M ago
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies
Premium
Company Announcements
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies
2M ago
Ovid Therapeutics sees cash runway into 2H26
Premium
The Fly
Ovid Therapeutics sees cash runway into 2H26
2M ago
Ovid Therapeutics upgraded to Outperform from Perform at Oppenheimer
PremiumThe FlyOvid Therapeutics upgraded to Outperform from Perform at Oppenheimer
3M ago
Ovid to present posters on pipeline program for neuronal hyperexcitability
Premium
The Fly
Ovid to present posters on pipeline program for neuronal hyperexcitability
5M ago
Ovid Therapeutics reports Q3 EPS (20c), consensus (20c)
Premium
The Fly
Ovid Therapeutics reports Q3 EPS (20c), consensus (20c)
6M ago
Ovid Therapeutics reduces headcount by 43%
PremiumThe FlyOvid Therapeutics reduces headcount by 43%
9M ago
Ovid Therapeutics reports cash position of $77M as of June 30
Premium
The Fly
Ovid Therapeutics reports cash position of $77M as of June 30
9M ago
Ovid Therapeutics reports Q2 EPS 12c, consensus (22c)
Premium
The Fly
Ovid Therapeutics reports Q2 EPS 12c, consensus (22c)
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100